Reviewing SIGA Technologies Inc. (SIGA)’s and Mesoblast Limited (NASDAQ:MESO)’s results

As Biotechnology companies, SIGA Technologies Inc. (NASDAQ:SIGA) and Mesoblast Limited (NASDAQ:MESO) are our subject to compare. And more specifically their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies Inc. 476.90M 1.11 359.11M 4.31 1.43
Mesoblast Limited 27.80M 15.29 47.77M -0.50 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of SIGA Technologies Inc. and Mesoblast Limited.

Profitability

Table 2 shows us SIGA Technologies Inc. and Mesoblast Limited’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
SIGA Technologies Inc. 75.30% -151.7% 261.2%
Mesoblast Limited -171.83% -8.7% -7%

Risk & Volatility

SIGA Technologies Inc.’s volatility measures that it’s 30.00% more volatile than S&P 500 due to its 1.3 beta. From a competition point of view, Mesoblast Limited has a 1.8 beta which is 80.00% more volatile compared to S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of SIGA Technologies Inc. are 21.8 and 21.3. Competitively, Mesoblast Limited has 3.6 and 3.6 for Current and Quick Ratio. SIGA Technologies Inc.’s better ability to pay short and long-term obligations than Mesoblast Limited.

Institutional and Insider Ownership

The shares of both SIGA Technologies Inc. and Mesoblast Limited are owned by institutional investors at 20.9% and 3% respectively. 1.9% are SIGA Technologies Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
SIGA Technologies Inc. -1.6% 18.76% -12.91% -13.28% 27.39% 26.6%
Mesoblast Limited -12.55% -47.53% -27.35% -30.56% -18.74% -27.23%

For the past year SIGA Technologies Inc. had bullish trend while Mesoblast Limited had bearish trend.

Summary

SIGA Technologies Inc. beats on 9 of the 11 factors Mesoblast Limited.

SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.